Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
about
Carcinoid tumorsGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsSomatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Multimodal management of neuroendocrine liver metastases.Somatostatin receptor based imaging and radionuclide therapy.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Stroma targeting nuclear imaging and radiopharmaceuticals.Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomasA review of the use of somatostatin analogs in oncologyThe Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.Continuing pursuit for ideal systemic anticancer radiotherapeutics.Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.Metastatic pheochromocytoma and paraganglioma.Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells.Radiolabeled peptides: valuable tools for the detection and treatment of cancerDesign and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.Successful Pregnancies after the Treatment of a Thymic CarcinoidSomatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.3D modeling of effects of increased oxygenation and activity concentration in tumors treated with radionuclides and antiangiogenic drugs.A Case of Malignant Metastatic Pheochromocytoma After Eight Years of Primary Diagnosis.Simultaneous double thymic carcinoids: a rare initial manifestation of multiple endocrine neoplasia type 1.Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential99mTC-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas
P2860
Q24614827-2ACDEEA6-5335-41E4-A2A0-40CAC75CA7EAQ28290833-AB5364D8-653D-4F54-B6F8-6BBEED3479F0Q34477028-3171AB94-07B3-4875-A7D2-D0628ADEE021Q34528199-345AE0A1-5CF2-49A4-A139-BB6E7D89974DQ35296661-5404E064-D9CF-405F-8A7B-AF4D866D812AQ35371197-3727F0CF-A0B6-4F73-9071-2851CBACF6CDQ35999606-1FEA9F6D-98E7-4757-8275-07BF1818758EQ36065515-72145BC7-B935-4669-B39C-1BD6416079B9Q36125143-3970884C-800C-44C1-A1BE-EC49F797B183Q36542866-D98E4C7D-8E28-401A-8425-0E3F99DF7FEEQ36661451-A8DE594B-EBCC-4DC0-8A67-14682A86F16DQ36804496-8019EE1B-74E6-4FAB-A794-BB6AD1DDD26EQ36833161-647AD088-3ECF-4598-B214-D7D903D9E177Q36962070-9347867E-368A-40C5-A5B5-FB7D0EDEA548Q37002905-B98E45D1-7BD8-46E9-B300-0D1594FBDA22Q37449406-0E4D9CA1-0FEE-44C7-AC2E-CEC665F2DB84Q37579225-1E24C0F5-811A-41F1-87E0-6B9CE149E124Q37812297-45B2122A-ED6C-4122-8115-BDB3656A9117Q37946750-89C22190-F1F9-4245-ACC0-FADE6659715AQ38169995-AC2503AF-F042-4603-8945-64548F7B8B35Q38548784-85E0FC91-23AF-4928-9649-9F1A9D2CF9F3Q38658730-DCDBBAEF-D3EC-4ECD-AE19-240AA052C2A9Q39588223-69464E9B-69F9-4B02-9093-6D7D0F061931Q39596344-447F0680-B3EF-4172-A914-8B6ECC625157Q39973557-FC03195F-2EAE-43C8-90FE-B9EBE3BBA501Q41954477-497FEB7C-3CC7-4218-A175-EC7EAC8DAAA4Q42548064-F7EF8A2C-FCA5-49F8-AF46-B6366B65CCEAQ45785165-817760DE-2F68-429F-9BE8-E5A1E9165BC9Q45821935-5A9BF4E4-CBB0-4AF8-B982-9CD3D97CCCD7Q50548955-81D50E0F-EC50-4315-ADE9-345D7983905FQ50847718-A84408CE-0F42-46D5-BD6D-589EBB42DFFDQ51160960-0AF2A6C3-26BF-4739-9C09-094D605CA4BDQ56992887-123BB3B4-880A-4077-9774-28633EC192E9Q56994395-BB904AC6-AAA8-45D0-981F-5541CDE9128E
P2860
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@ast
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@en
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@nl
type
label
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@ast
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@en
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@nl
prefLabel
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@ast
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@en
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@nl
P2093
P356
P1476
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
@en
P2093
A B Grossman
D Papadogias
G A Kaltsas
P304
P356
10.1677/ERC.1.01116
P577
2005-12-01T00:00:00Z